OliPass

OliPass EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OliPass (244460.KQ) as of Oct 21, 2026 is -9.68 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -13.00 B KRW — a change of -25.50% (higher).

EBITDA

-9.68 BKRW

YoY

-25.50%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OliPass is 2024 -9.68 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OliPass was 2023 -13.00 B KRW. It decreases by -25.50% higher compared to the previous year.

The OliPass EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-12.52 B KRW
Jan 1, 2018
-17.06 B KRW
Jan 1, 2019
-20.35 B KRW
Jan 1, 2020
-22.57 B KRW
Jan 1, 2021
-23.38 B KRW
Jan 1, 2022
-22.86 B KRW
Jan 1, 2023
-13.00 B KRW
Jan 1, 2024
-9.68 B KRW
The OliPass EBITDA history
YEAREBITDAYoY
-9.68 BKRW-25.50%
-13.00 BKRW-43.14%
-22.86 BKRW-2.22%
-23.38 BKRW+3.58%
-22.57 BKRW+10.90%
-20.35 BKRW+19.26%
-17.06 BKRW+36.29%
-12.52 BKRW+10.80%
-11.30 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OliPass Stock analysis

What does OliPass do? OliPass Corp develops and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, and cancer immunotherapy medicine. The company also researches, develops, and sells functional cosmetics using artificial gene platform technology. Its primary customers are healthcare providers and pharmaceutical companies seeking innovative treatments and cosmetic solutions. OliPass Corp generates revenue through the sale of these medical products and functional cosmetics, focusing on biotechnology-driven healthcare and beauty markets. The company's product portfolio includes nonopioid analgesics for pain management, hyperlipidemia medicines for cholesterol control, ocular angiogenesis inhibitors for eye conditions, duchenne dystrophy treatments, and cancer immunotherapy medicines. Functional cosmetics developed via artificial gene platform technology target consumers interested in advanced skincare. OliPass Corp's revenue streams are derived from direct sales to healthcare institutions and pharmaceutical distributors, with a strong emphasis on biotech innovation in both medicine and cosmetics. OliPass Corp's business model centers on developing proprietary biological products through research and development. The firm sells its medicines and functional cosmetics to healthcare providers and pharmaceutical companies, leveraging its artificial gene platform technology for product differentiation. Revenue is generated through the commercialization of its medical and cosmetic product lines, which cater to specific health and beauty segments requiring advanced biotechnological solutions. OliPass is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OliPass stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OliPass is -9.68 B KRW in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OliPass changed from -13.00 B KRW to -9.68 B KRW, representing a -25.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) OliPass since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s OliPass historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — OliPass

All Key Metrics — OliPass